KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Receivables (2018 - 2025)

ClearPoint Neuro's Receivables history spans 13 years, with the latest figure at $5.3 million for Q3 2025.

  • For Q3 2025, Receivables rose 15.85% year-over-year to $5.3 million; the TTM value through Sep 2025 reached $5.3 million, up 15.85%, while the annual FY2024 figure was $4.7 million, 19.5% up from the prior year.
  • Receivables for Q3 2025 was $5.3 million at ClearPoint Neuro, up from $4.8 million in the prior quarter.
  • Across five years, Receivables topped out at $5.4 million in Q4 2024 and bottomed at $2.1 million in Q1 2021.
  • The 5-year median for Receivables is $3.0 million (2023), against an average of $3.4 million.
  • The largest annual shift saw Receivables soared 91.86% in 2021 before it dropped 16.4% in 2023.
  • A 5-year view of Receivables shows it stood at $2.4 million in 2021, then grew by 22.77% to $3.0 million in 2022, then surged by 31.82% to $3.9 million in 2023, then soared by 35.78% to $5.4 million in 2024, then dropped by 1.85% to $5.3 million in 2025.
  • Per Business Quant, the three most recent readings for CLPT's Receivables are $5.3 million (Q3 2025), $4.8 million (Q2 2025), and $3.8 million (Q1 2025).